#pharma
An exclusive analysis conducted by Talkwalker for PharmaTimes reveals which companies are the most successful at using social media and what they’re doing right
Ahead of our Marketer of the Year awards ceremony in November, we thought we’d take a look at some of the most important tools available to modern pharma marketers.
Social media is increasingly important for all industries. Pharma might face an uphill battle to be heard among a sea of celebrities and breaking news -- but as shown in this month’s cover feature (p34), with exclusive research conducted for PharmaTimes, companies are already starting to figure out what works best.
Of course, social media is just one channel among many that marketers can harness to get their message across, and these days marketing is really about multichannel strategies. That said, research shows that the European industry is falling behind in this area, so in The Secrets of Multichannel (p31) we ask how they can start to close the gap.
Other articles this month include a look at an exciting new gene therapy delivery technology (p28), an interview with Bayer’s new UK & Ireland CEO Lars Bruening (p39) and a focus on joint working in IBD Registry Industry Working Group (p20) -- along with a Patient Files focusing on ulcerative colitis (p45).
An exclusive analysis conducted by Talkwalker for PharmaTimes reveals which companies are the most successful at using social media and what they’re doing right
Europe is lagging when it comes to multichannel engagement. What are the secrets to making it a success?
Sue Thomas and Paul Midgley of Wilmington Healthcare explore how the proposed national patient data sharing scheme would change the NHS
Richard Gardner, British Society of Gastroenterology chief executive, and Jeremy Thorpe, general manager of Tillotts Pharma UK, explain the value of joint working in IBD
How can blockchain help the pharma supply chain?
What does the new Criminal Finance Act mean for pharma?
Biotech firm Nanogenics believes that its product LipTide could solve one of the oldest problems in gene therapy – delivery. Director of business development Alan Walker and director of pre-clinical development Simon Newman talk to PharmaTimes about their vision for the company and LipTide
Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future
Five years on from Pfizer selling Discovery Park, the site’s current chief executive Toby Hunter tells PharmaTimes about the plans for its future
Charlotte Guinea talks about her experiences with this ‘invisible disease’